UBS Group’s GSK PLC ADRhedged GSKH Stock Holding History

UBS Group’s Portfolio GSKH Stock Details GSKH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-3	Closed	-$222	–	11839
2026 Q2	$222	Buy	+3	New	+$223	﹤0.01%	9985
2026 Q1	–	Sell	-65	Closed	-$4.43K	–	11490
2025 Q4	$4.43K	Sell	65 -35	-35%	-$2.32K	﹤0.01%	8838
2025 Q3	$6.08K	Sell	100 -33	-25%	-$1.81K	﹤0.01%	8808
2025 Q2	$6.99K	Buy	133 +100	+303%	+$5.35K	﹤0.01%	9047
2025 Q1	$1.84K	Buy	+33	New	+$1.78K	﹤0.01%	9437

Other funds holding GSKH

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group's GSKH Position: Q3 2026 in Review

UBS Group sold out of GSK PLC ADRhedged (GSKH) in Q3 2026, closing a stake of 3 shares — an estimated $222 sold.

UBS Group first reported a position in GSKH in Q1 2025 and held it in 5 quarters. The position peaked at $6.99K in Q2 2025. 1 fund tracked by Wall St. Rank holds GSKH as of Q3 2026.

UBS Group reported no remaining GSK PLC ADRhedged position as of Q3 2026 after selling out during the quarter.
UBS Group sold 3 GSK PLC ADRhedged shares in Q3 2026, an estimated $222.
UBS Group first reported a position in GSK PLC ADRhedged in Q1 2025 and held it in 5 quarters.
UBS Group's GSK PLC ADRhedged position peaked at $6.99K in Q2 2025.
1 fund tracked by Wall St. Rank held GSK PLC ADRhedged as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.